NEW
YORK, Feb. 2, 2024 /PRNewswire/ -- The Gross Law
Firm issues the following notice to shareholders of Eagle
Pharmaceuticals, Inc..
Shareholders who purchased shares of EGRX during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/eagle-pharmaceuticals-inc-loss-submission-form/?id=65521&from=4
CLASS PERIOD: August 8,
2023 to November 28, 2023
ALLEGATIONS: The complaint alleges that
during the class period, Defendants issued materially false and/or
misleading statements and/or failed to disclose that: (1) that the
Company was experiencing slower-than anticipated pull-though from a
wholesale customer predominantly due to expiry of inventory; (2)
that, as a result, the Company had overstated its revenue; (3) that
the Company did not have effective internal controls and procedures
over financial reporting as to sales of PEMFEXY, Eagle
Pharmaceuticals' metabolic inhibitor product; and (4) as a result
of the foregoing, defendants' positive statements about the
Company's business, operations, and prospects were materially
misleading and/or lacked a reasonable basis.
DEADLINE: February 9, 2024
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/eagle-pharmaceuticals-inc-loss-submission-form/?id=65521&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of EGRX during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is February 9, 2024. There is no cost
or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-eagle-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-february-9-2024--nasdaq-egrx-302051557.html
SOURCE The Gross Law Firm